- Home
- MX vs VTYX Comparison
MX vs VTYX Comparison
Compare MX & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MX
- VTYX
- Stock Information
- Founded
- MX 2003
- VTYX 2018
- Country
- MX South Korea
- VTYX United States
- Employees
- MX N/A
- VTYX N/A
- Industry
- MX Semiconductors
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- MX Technology
- VTYX Health Care
- Exchange
- MX Nasdaq
- VTYX Nasdaq
- Market Cap
- MX 149.6M
- VTYX 154.9M
- IPO Year
- MX N/A
- VTYX 2021
- Fundamental
- Price
- MX $4.61
- VTYX $1.84
- Analyst Decision
- MX Strong Buy
- VTYX Buy
- Analyst Count
- MX 2
- VTYX 4
- Target Price
- MX $7.50
- VTYX $11.33
- AVG Volume (30 Days)
- MX 198.7K
- VTYX 1.9M
- Earning Date
- MX 02-14-2025
- VTYX 02-25-2025
- Dividend Yield
- MX N/A
- VTYX N/A
- EPS Growth
- MX N/A
- VTYX N/A
- EPS
- MX N/A
- VTYX N/A
- Revenue
- MX $219,520,000.00
- VTYX N/A
- Revenue This Year
- MX $3.09
- VTYX N/A
- Revenue Next Year
- MX $10.06
- VTYX N/A
- P/E Ratio
- MX N/A
- VTYX N/A
- Revenue Growth
- MX N/A
- VTYX N/A
- 52 Week Low
- MX $3.56
- VTYX $1.67
- 52 Week High
- MX $6.93
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- MX 68.95
- VTYX 39.45
- Support Level
- MX $3.93
- VTYX $1.91
- Resistance Level
- MX $4.17
- VTYX $2.15
- Average True Range (ATR)
- MX 0.16
- VTYX 0.16
- MACD
- MX 0.03
- VTYX -0.02
- Stochastic Oscillator
- MX 64.66
- VTYX 4.08
About MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.